Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG3067 and the Combination of GLPG3067 and GLPG2222 in Healthy Female Subjects, Including a Relative Bioavailability and Food Effect Part for Single Dose of GLPG3067
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
At a glance
- Drugs GLPG 2222 (Primary) ; GLPG 3067 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man
- Sponsors Galapagos NV
- 20 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.
- 20 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2018.
- 22 Aug 2017 Planned number of patients changed from 65 to 81.